GRCL Stock Recent News

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , Sept.

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , June.

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , May 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will present updated clinical data from a multicenter investigator-initiated trial (IIT) evaluating GC012F, the company's B-cell maturation antigen (BCMA) and CD19 dual-targeting CAR-T candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM) in an oral abstract presentation at the 2022 American Society of Clinical Oncology (ASCO 2022) Annual Meeting.

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in June 2022 as follows: BTIG China Biotech Day (Virtual) Fireside chat: June One-on-one meetings: June 1 To listen to the live event, please contact your BTIG representative.

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Dr. William Cao - Founder, Chairman, and CEO Dr. Martina Sersch - CMO Dr. Kevin Xie - CFO Conference Call Participants Joe Catanzaro - Piper Sandler Kelly Shi - Jefferies Nick Abbott - Wells Fargo Operator Ladies and gentlemen, thank you for standing by. Welcome to the Gracell Biotechnologies First Quarter 2022 Conference Call.

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of three abstracts that it will present at the European Hematology Association 2022 Hybrid Congress (EHA2022 Congress), being held from June 9 – June 12 in Vienna, Austria.